#OakVar Report
#Created at Monday 02/26/2024 01:58:15
#Report level: variant
#
Variant Annotation																Samples and Tags				Original Input					pmkb							
UID	Chrom	Position	End Position	Ref Base	Alt Base	Tags	Coding	Gene	Transcript	Sequence Ontology	cDNA change	Protein Change	Exon number	All Mappings	RefSeq	Genotypes	Sample Count	Samples	Tags	Chrom	Pos	End Position	Reference allele	Alternate allele	gene_name	tumor_type	tissue_type	pmkb_url_interpretation	interpretations	citations	achange	pmkb_url_variants
1	chr10	87894027	87894027	-	CT		Yes	PTEN	ENST00000371953.8	frameshift_elongation	c.81_82insCT	p.Ile28LeufsTer27	2	ENST00000371953.8:PTEN:P60484:frameshift_elongation:p.Ile28LeufsTer27:c.81_82insCT:2; ENST00000462694.1:PTEN::retained_intron:::2; ENST00000472832.3:PTEN:A0A087X033:frameshift_elongation:p.Ile28LeufsTer27:c.81_82insCT:2; ENST00000686459.1:PTEN:A0A8I5KVQ8:frameshift_elongation,NMD_transcript_variant:p.Ile28LeufsTer27:c.81_82insCT:2; ENST00000688158.2:PTEN::intron_variant,unknown:::4; ENST00000688308.1:PTEN:P60484:frameshift_elongation:p.Ile28LeufsTer27:c.81_82insCT:3; ENST00000688922.2:PTEN:A0A8I5KR36:frameshift_elongation,NMD_transcript_variant:p.Ile28LeufsTer27:c.81_82insCT:2; ENST00000700021.1:PTEN::frameshift_elongation:p.Ile28LeufsTer27:c.81_82insCT:2; ENST00000700022.1:PTEN::frameshift_elongation,NMD_transcript_variant:p.Ile28LeufsTer27:c.81_82insCT:2; ENST00000706954.1:PTEN:F6KD01:frameshift_elongation:p.Ile28LeufsTer27:c.81_82insCT:3; ENST00000706955.1:PTEN::NMD_transcript_variant,3_prime_UTR_variant::c.*116_*117insCT:4	NM_000314		1	s3		chr10	87894027		-	CT	PTEN	T Lymphoblastic Leukemia/Lymphoma	Blood|Bone Marrow	http://pmkb.weill.cornell.edu/therapies/41	PTEN is a lipid and protein phosphatase that negatively regulates the PI3K/AKT/mTOR pathway.  PTEN has been reported to show nonsense and frameshift mutations in approximately 10% of adult T cell ALL patients. PTEN mutations may occur together with large deletions of PTEN which are not detected by this assay.  PTEN abnormalities are thought to be more frequent in NOTCH1/FBXW7 unmutated T-ALL and appear to be mutually exclusive of NRAS/KRAS mutations in T-ALL. PTEN alterations are associated with reduced or absent protein expression and may be associated with a poor prognosis in adult T cell ALL, but not pediatric T-ALL, according to some studies. PTEN alterations appear to be infrequent among myeloid malignancies.	Trinquand A, et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol 2013;31(34):4333-42|Zuurbier L, et al. The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia. Haematologica 2012;97(9):1405-13	_codon:_any:_any:_any:_any	http://pmkb.weill.cornell.edu/variants/2676
2	chr1	114713881	114713885	TGGTC	-		Yes	NRAS	ENST00000369535.5	frameshift_truncation	c.205_209del	p.Asp69IlefsTer16	3	ENST00000369535.5:NRAS:P01111:frameshift_truncation:p.Asp69IlefsTer16:c.205_209del:3	NM_002524		1	s1		chr1	114713881		TGGTC	-	NRAS	Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome|B Lymphoblastic Leukemia/Lymphoma|Acute Leukemia of Unspecified Cell Type|Anemia, Unspecified|Atypical Chronic Myeloid Leukemia|Chronic Myeloid Leukemia|Chronic Neutrophilic Leukemia|Cytopenia|Eosinophilia|Essential Thrombocythemia|Histiocytic and Dendritic Cell Neoplasms|Langerhans Cell Histiocytosis|Leukocytosis|Leukopenia|Mast Cell Neoplasm|MDS with Ring Sideroblasts|Monocytosis|Myelodysplastic/Myeloproliferative Neoplasm|Myeloproliferative Neoplasm|Myeloid Neoplasm|Other Acute Leukemia|Polycythemia Vera|Polycythemia|Primary Myelofibrosis|T Lymphoblastic Leukemia/Lymphoma|Thrombocytopenia, Unspecified|Thrombocytosis	Blood|Bone Marrow	http://pmkb.weill.cornell.edu/therapies/4	NRAS encodes a membrane protein GTPase that is a central mediator of downstream growth factor receptor signaling, critical for cell proliferation and survival.  Mutations in codons 12, 13, and 61 of NRAS have been reported in 7-22% of acute myeloid leukemia,  12% of chronic myelomonocytic leukemia,  20% of blastic plasmacytoid dendritic cell neoplasm,  16% of juvenile myelomonocytic leukemia, 4-10% of myelodysplastic syndromes, and 5% of primary myelofibrosis. In addition, NRAS mutations have been described in approximately 15% of cases of B-ALL and, interestingly, some cases of ALL may show more than one abnormality in the RAS pathway.  NRAS mutations are associated with an unfavorable prognosis in chronic myelomonocytic leukemia and primary myelofibrosis. NRAS mutations are also associated with an unfavorable prognosis in myelodysplastic syndrome, particularly in patients predicted to have lower-risk myelodysplastic syndrome (NCCN Guidelines for Myelodysplastic Syndromes).  NRAS mutations do not seem to have significant prognostic impact in AML.	Jain N, et al. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res 2014;20(2):490-8|Murphy DM, et al. NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes. Leukemia 2013;27(10):2077-81|Bejar R, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364(26):2496-506|Bacher U, et al. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 2007;92(6):744-52|Dicker F, et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia 2010;24(8):1528-32|Ricci C, et al. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res 2010;16(8):2246-56|Tyner JW, et al. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood 2009;113(8):1749-55|Al-Kali A, et al. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol 2013;88(5):365-9|Zhang J, et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011;118(11):3080-7|Bacher U, et al. Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006;107(10):3847-53|Metzeler KH, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood 2016;128(5):686-98|Menezes J, et al. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia 2014;28(4):823-9|Sakaguchi H, et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet 2013;45(8):937-41|Elena C, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood 2016;128(10):1408-17|Tenedini E, et al. Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. Leukemia 2014;28(5):1052-9|Haferlach T, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014;28(2):241-7|Burgess MR, et al. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood 2014;124(26):3947-55	_codon:_any:_any:_any:_any	http://pmkb.weill.cornell.edu/variants/2618
3	chr4	1804372	1804372	A	G		Yes	FGFR3	ENST00000440486.8	missense_variant	c.1118A>G	p.Tyr373Cys	9	ENST00000260795.8:FGFR3:I6LM06:NMD_transcript_variant,3_prime_UTR_variant::c.*174A>G:10; ENST00000340107.9:FGFR3:P22607:missense_variant:p.Tyr375Cys:c.1124A>G:9; ENST00000352904.6:FGFR3:P22607:intron_variant::c.931-452A>G:6; ENST00000412135.7:FGFR3:A0A7I2RW32:missense_variant:p.Tyr369Cys:c.1106A>G:9; ENST00000440486.8:FGFR3:P22607:missense_variant:p.Tyr373Cys:c.1118A>G:9; ENST00000469068.1:FGFR3::2kb_upstream_variant,retained_intron:::0; ENST00000474521.1:FGFR3::2kb_downstream_variant,retained_intron:::0; ENST00000481110.7:FGFR3:F8W9L4:missense_variant:p.Tyr373Cys:c.1118A>G:9; ENST00000643463.1:FGFR3::unknown:::3	NM_000142		1	s1		chr4	1804372		A	G	FGFR3	Carcinoma|Urothelial Carcinoma	Bladder	http://pmkb.weill.cornell.edu/therapies/137	FGFR3 has been found to be mutated in up to 64% of cases of bladder cancer; FGFR3 mutations tend to be exclusive of RAS mutations ,TP53 overexpression, TP53 mutation, but not PIK3CA mutations. However, subsets of cases with co-mutations have been described. FGFR3 mutations (including Y373C) are believed to lead to constitutive activation of the receptor and activation of the RAS-MAPK pathway. FGFR3 mutations are often seen in non-muscle invasive bladder cancers and tend to correlate with low stage and grade; however FGFR3 mutations have also been described in muscle-invasive bladder cancer. Targeted therapies with FGFR3 inhibitors have been explored in patients with bladder cancer.	Kompier LC, Lurkin I, van der Aa MNM, van Rhijn BWG, van der Kwast TH, et al. (2010) FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy. PLoS ONE 5(11): e13821.|Chell V, Balmanno K, Little AS, Wilson M, Andrews S, Blockley L, Hampson M, Gavine PR, Cook SJ. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene. 2013 Jun 20;32(25):3059-70|Ronchetti D, Greco A, Compasso S, Colombo G, Dell'Era P, Otsuki T, Lombardi L, Neri A. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene. 2001 Jun 14;20(27):3553-62. PubMed PMID: 11429702.	_codon:373:373:missense:Y:C	http://pmkb.weill.cornell.edu/variants/249
4	chr7	140753351	140753351	A	G		Yes	BRAF	ENST00000646891.2	missense_variant	c.1784T>C	p.Phe595Ser	15	ENST00000288602.11:BRAF:A0A2U3TZI2:missense_variant:p.Phe635Ser:c.1904T>C:16; ENST00000496384.7:BRAF:H7C560:missense_variant:p.Phe595Ser:c.1784T>C:15; ENST00000497784.2:BRAF:H7C5K3:NMD_transcript_variant,3_prime_UTR_variant::c.*1234T>C:16; ENST00000642228.1:BRAF:A0A2R8Y467:NMD_transcript_variant,3_prime_UTR_variant::c.*862T>C:15; ENST00000642875.1:BRAF::intron_variant,retained_intron:::11; ENST00000644120.1:BRAF::unknown:::14; ENST00000644905.1:BRAF::retained_intron:::15; ENST00000644969.2:BRAF:A0A2R8Y8E0:missense_variant:p.Phe635Ser:c.1904T>C:16; ENST00000646730.1:BRAF:A0A2R8YDP5:NMD_transcript_variant,3_prime_UTR_variant::c.*360T>C:17; ENST00000646891.2:BRAF:P15056:missense_variant:p.Phe595Ser:c.1784T>C:15	NM_004333		1	s0		chr7	140753351		A	G	BRAF	Acute Leukemia of Unspecified Cell Type|Acute Myeloid Leukemia|Anemia, Unspecified|Atypical Chronic Myeloid Leukemia|B Lymphoblastic Leukemia/Lymphoma|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Cytopenia|Eosinophilia|Essential Thrombocythemia|Leukocytosis|Leukopenia|Mast Cell Neoplasm|MDS with Ring Sideroblasts|Monocytosis|Myelodysplastic Syndrome|Myelodysplastic/Myeloproliferative Neoplasm|Myeloproliferative Neoplasm|Myeloid Neoplasm|Other Acute Leukemia|Polycythemia Vera|Polycythemia|Primary Myelofibrosis|T Lymphoblastic Leukemia/Lymphoma|Thrombocytopenia, Unspecified|Thrombocytosis|Chronic Lymphocytic Leukemia|Diffuse Large B Cell Lymphoma	Blood|Bone Marrow	http://pmkb.weill.cornell.edu/therapies/33	B-RAF is a member of the RAF-family of kinases which plays an important role in the RAS-RAF-MEK-ERK mitotic signaling pathway.  Mutations of B-RAF have been described in up to 100% of Hairy cell leukemia, 40-70% of  Langerhans cell histiocytosis, approximately 50% of Erdheim-Chester disease,  approximately 5% of diffuse large B cell lymphoma and plasma cell neoplasms and less than 5% of chronic lymphocytic leukemia.  While some reports have found that 10-20% of cases of acute leukemias (ALL or AML) may have BRAF mutations, other reports have described no BRAF in those diseases or in myeloid diseases such as MDS or CML. The hotspot for mutations in BRAF is at codon Val600 and these are activating mutations.  The most common activating mutation is p.Val600Glu(V600E).  Various B-Raf inhibitors(Vemurafenib, Dabrafenib) have been FDA approved for therapy for some tumor types in certain clinical settings.	Machnicki MM, et al. BRAF--a new player in hematological neoplasms. Blood Cells Mol Dis 2014;53(1-2):77-83|Alonso CM, et al. BRAF V600E mutation in adult acute lymphoblastic leukemia. Leuk Lymphoma 2013;54(5):1105-6|Langabeer SE, et al. Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemia. Leuk Res 2012;36(4):483-4|Jebaraj BM, et al. BRAF mutations in chronic lymphocytic leukemia. Leuk Lymphoma 2013;54(6):1177-82|Ping N, et al. Absence of BRAF V600E mutation in hematologic malignancies excluding hairy-cell leukemia. Leuk Lymphoma 2012;53(12):2498-9|Samuel J, et al. Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med 2014;370(3):286-8	_codon:595:595:missense:F:S	http://pmkb.weill.cornell.edu/variants/398
#OakVar Report
#Created at Monday 02/26/2024 01:58:15
#Report level: gene
#
Variant Annotation	
Gene	Note
BRAF	
FGFR3	
NRAS	
PTEN	
#OakVar Report
#Created at Monday 02/26/2024 01:58:16
#Report level: sample
#
Variant Annotation	
UID	Sample
1	s3
2	s1
3	s1
4	s0
#OakVar Report
#Created at Monday 02/26/2024 01:58:16
#Report level: mapping
#
Variant Annotation			
Original Line	Tags	UID	Input file number
1		1	0
2		2	0
3		3	0
4		4	0
